HealthViiV Healthcare's Cabenuva Shows Superior Viral Suppression in HIV Patients
ViiV Healthcare announced that its long-acting HIV treatment, Cabenuva (cabotegravir + rilpivirine), has met the primary endpoint by demonstrating superior viral suppression compared to daily oral therapy in people with viremia. This advancement offers a promising alternative for HIV patients seeking effective treatment with less frequent dosing.
European AIDS Treatment Group·



